Merck’s Phase 3 Keynote- A18 trial met PFS in patients with advanced cervical cancer
KEYTRUDA plus concurrent chemoradiotherapy demonstrated statistically significant and clinically meaningful improvement in PFS versus concurrent chemoradiotherapy alone in these patients